Recent breakthrough results from immune checkpoint inhibitors (ICI) have paved the way to
a new era of cancer immunotherapy. In particular, inhibition of programmed death-1 (PD …

Chronic inflammation may increase the risk to develop cancer, for instance esophagitis or
gastritis may lead to development of esophageal or gastric cancer, respectively. The key …

The increase in the use of nanoparticles, as a promising tool for drug delivery or as a food
additive, raises questions about their interaction with biological systems, especially in terms …

Helicobacter pylori (H. pylori) is a major etiological factor in the development of gastric
cancer. Large-scale epidemiological studies have confirmed the strong association between …

Gastric cancer is one of leading causes of cancer‑related mortality worldwide and is a
notable disease due to its heterogeneity. Recently, numerous studies have investigated the …

Helicobacter pylori is a highly prevalent human pathogen responsible for chronic
inflammation of the gastric tissues, gastroduodenal ulcers, and cancer. The treatment …

The humoral innate immune response consists of multiple components, including the
naturally occurring antibodies (NAb), pentraxins and the complement and contact cascades …

Chronic inflammation plays a decisive role at different stages of cancer development.
Inflammasomes are oligomeric protein complexes activated in response to pathogen …

Cachexia, a paraneoplastic syndrome markedly associated with worsened prognosis in
cancer patients, provokes profound wasting of both lean and adipose mass in an …

Background: Patients with gastric cancer (GC) commonly exhibit a hypercoagulable state
that results in significant morbidity and mortality. Recent studies have shown that neutrophil …